Identifying and developing products that will improve the health and quality of life of patients remains a primary focus of Forest Laboratories.
05.14.2012 - Ironwood and Forest to Present 17 Linaclotide-Related Abstracts at Digestive Disease Week® 2012
05.04.2012 - Forest Laboratories, Inc. to Present Cariprazine and Levomilnacipran Results from Phase 3 Trials at American Psychiatric Association (APA) Annual Meeting
04.26.2012 - Forest Laboratories, Inc. and Pierre Fabre Medicament Announce Third Positive Phase III Study for Levomilnacipran in Patients with Major Depressive Disorder
04.23.2012 - Ironwood and Forest Announce FDA has Extended the Review Period for Linaclotide to September 2012